<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725387</url>
  </required_header>
  <id_info>
    <org_study_id>VAR0024</org_study_id>
    <secondary_id>98043</secondary_id>
    <secondary_id>SU-07232008-1266</secondary_id>
    <nct_id>NCT00725387</nct_id>
  </id_info>
  <brief_title>Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy</brief_title>
  <official_title>Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool
      for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used
      in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT
      scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for
      cancer detection was not attempted to date. We hope to learn what is the best approach for
      detection of cancer and thus to improve cancer treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.</measure>
    <time_frame>not defined</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be referred for evaluation of bone metastases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18-year-old, diagnosed with cancer

          -  Patients must understand and voluntarily sign an Informed Consent form after the
             contents have been fully explained to them

        Exclusion Criteria:

          -  Patients who cannot complete a PET/CT scan

          -  Pregnant women

          -  Healthy volunteers

          -  Patients participating in other research studies

        The subjects will not be paid to participate in this protocol. No costs will be charged to
        the subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>650-736-2859</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>(650) 498-7061</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrei Iagaru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>(650) 736-2859</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Vineet Prakash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>650-736-2859</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jyotsna Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coimbra University Hospital</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>650-736-2859</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jo Manuel Pedroso de Lima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pretoria Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>650-736-2859</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Mike Sathekge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>India</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
